6-mercapto-9-(tetrahydro-2-furyl)purine and Dengue

6-mercapto-9-(tetrahydro-2-furyl)purine has been researched along with Dengue* in 1 studies

Other Studies

1 other study(ies) available for 6-mercapto-9-(tetrahydro-2-furyl)purine and Dengue

ArticleYear
Treatment of intracranial dengue virus infections in mice with a lipophilic derivative of ribavirin.
    Antimicrobial agents and chemotherapy, 1983, Volume: 24, Issue:1

    Rimantadine, ribavirin, and 6-mercapto-9-(tetrahydro-2-furyl)purine, administered intraperitoneally every 8 h for 7 days starting minutes after virus challenge, had no effect on survival and mean survival time of BALB/c mice inoculated intracranially with dengue virus type 2. In contrast, intraperitoneal treatment with ribavirin 2',3',5'-triacetate, a lipophilic analog of ribavirin, effected significant increases in both mean survival time and survival rate, suggesting that ribavirin 2',3',5'-triacetate may be superior to rabavirin for treatment of viral diseases of the brain.

    Topics: Adamantane; Animals; Brain Diseases; Dengue; Female; Mercaptopurine; Mice; Mice, Inbred BALB C; Ribavirin; Ribonucleosides; Rimantadine

1983